Silver Book Fact

A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s disease and $12,294/QALY for patients with advanced disease.

Hoerger T, Bala M, Rowland C, Greer M, et al. Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S. Pharmacoeconomics. 1998; 14(5): 541-57. http://www.ncbi.nlm.nih.gov/pubmed/10344917

Reference

Title
Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S.
Publication
Pharmacoeconomics
Publication Date
1998
Authors
Hoerger T, Bala M, Rowland C, Greer M, et al.
Volume & Issue
Volume 14, Issue 5
Pages
541-57
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Medicaid Costs, Slowed Progression  
  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.  
  • One study shows that electrical spinal cord stimulation significantly improved motor function in an animal model of Parkinson’s disease.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the total costs of care for people with the disease by…  
  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.